DK0957903T3 - Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser - Google Patents

Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser

Info

Publication number
DK0957903T3
DK0957903T3 DK97944319T DK97944319T DK0957903T3 DK 0957903 T3 DK0957903 T3 DK 0957903T3 DK 97944319 T DK97944319 T DK 97944319T DK 97944319 T DK97944319 T DK 97944319T DK 0957903 T3 DK0957903 T3 DK 0957903T3
Authority
DK
Denmark
Prior art keywords
disorders
norbornanediol
norbornene
compounds
treatment
Prior art date
Application number
DK97944319T
Other languages
English (en)
Inventor
Krystyna Lesiak
David A Brown
Alexander A Khorlin
Wu Yun Ren
Original Assignee
Applied Genetics Inc Dermatics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetics Inc Dermatics filed Critical Applied Genetics Inc Dermatics
Application granted granted Critical
Publication of DK0957903T3 publication Critical patent/DK0957903T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK97944319T 1996-09-18 1997-09-18 Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser DK0957903T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2657796P 1996-09-18 1996-09-18
US3594797P 1997-01-21 1997-01-21
US3686397P 1997-02-04 1997-02-04
US4859797P 1997-06-04 1997-06-04

Publications (1)

Publication Number Publication Date
DK0957903T3 true DK0957903T3 (da) 2005-11-21

Family

ID=27487517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97944319T DK0957903T3 (da) 1996-09-18 1997-09-18 Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser

Country Status (9)

Country Link
US (2) US6294585B1 (da)
EP (1) EP0957903B1 (da)
AT (1) ATE301459T1 (da)
AU (1) AU740783B2 (da)
CA (1) CA2266496A1 (da)
DE (1) DE69733968T2 (da)
DK (1) DK0957903T3 (da)
ES (1) ES2245465T3 (da)
WO (1) WO1998011882A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
AU740783B2 (en) 1996-09-18 2001-11-15 Applied Genetics Incorporated Dermatics Pharmaceutical compositions and methods
US6214888B1 (en) 1996-09-18 2001-04-10 Applied Genetics Incorporated Dermatological compounds
WO1998033379A1 (en) * 1997-02-04 1998-08-06 The General Hospital Corporation A novel method for treating epidermal or dermal conditions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6267948B1 (en) 1998-04-06 2001-07-31 Applied Genetics Incorporated Dermatics Dermatological formulations and methods
EP1087782A4 (en) * 1998-06-15 2001-09-12 Neuronz Ltd REGULATION OF TYROSINE HYDROXYLASE
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
US6359153B1 (en) * 1998-10-28 2002-03-19 Hyundai Electronics Industries Co., Ltd. Photoresist monomers and preparation thereof
AU2000238755A1 (en) * 2000-03-10 2001-09-24 Applied Genetics Incorporated Dermatics Dermatological compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20040192638A1 (en) * 2001-07-02 2004-09-30 Oaks John A. Method and composition for prolonging the residence time of drugs in the gut
CA2451360A1 (en) * 2001-07-02 2003-01-16 Wisconsin Alumni Research Foundation Method and composition for prolonging the residence time of drugs in the gut
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2004242507B2 (en) * 2002-06-12 2009-02-19 Piotr Chomczynski Method of treating rosacea
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
FR2856926B1 (fr) * 2003-07-02 2005-09-30 Centre Nat Rech Scient Utilisation des n-alkanols comme activateurs du canal cftr
US10350428B2 (en) 2014-11-04 2019-07-16 Endonovo Therapetics, Inc. Method and apparatus for electromagnetic treatment of living systems
US9415233B2 (en) 2003-12-05 2016-08-16 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological pain
US8961385B2 (en) 2003-12-05 2015-02-24 Ivivi Health Sciences, Llc Devices and method for treatment of degenerative joint diseases with electromagnetic fields
US9656096B2 (en) 2003-12-05 2017-05-23 Rio Grande Neurosciences, Inc. Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans
US9433797B2 (en) 2003-12-05 2016-09-06 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurodegenerative conditions
US9427598B2 (en) 2010-10-01 2016-08-30 Rio Grande Neurosciences, Inc. Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans
US9440089B2 (en) 2003-12-05 2016-09-13 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke
BRPI0509444A (pt) 2004-04-19 2007-09-04 Ivivi Technologies Inc método para o tratamento eletromagnético de tecidos e células vivos através da intensificação da angiogênese e da neovascularização, aparelho de tratamento eletromagnético e dispositivo gerador de sinais eletromagnéticos
JP2008500368A (ja) * 2004-05-27 2008-01-10 ミジェニックス コーポレイション 細胞保護のための２置換１７−イミノエストロゲン化合物
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US9579298B2 (en) * 2004-12-02 2017-02-28 Piotr Chomczynski Antioxidant dietary supplement compositions and methods for maintaining healthy skin
FR2889808B1 (fr) 2005-08-17 2011-07-22 Oreal Utilisation de l'acide 8-hexadecene-1,16-dicarboxylique comme agent de soin destine a favoriser la cohesion de la couche cornee
WO2007048034A2 (en) * 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of androgens for the treatment of parkinson' s disease
KR101111020B1 (ko) * 2006-07-04 2012-03-13 주식회사 알엔에스 신규한 사이클릭 화합물의 유도체 및 그의 용도
EP2066393A1 (en) * 2006-09-20 2009-06-10 IVIVI Technologies, Inc. Electromagnetic apparatus for respiratory disease and method for using same
US20080247543A1 (en) * 2007-02-22 2008-10-09 Colin Kennedy Mick Method and apparatus for protecting digital rights of copyright holders of publicly distributed multimedia files
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
WO2009046322A2 (en) * 2007-10-03 2009-04-09 Florida Atlantic University Compositions and methods for treating neural anoxia and spreading depression
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
PE20130775A1 (es) * 2010-05-27 2013-07-21 Targacept Inc Antagonistas no competitivos de receptores nicotinicos
ITMI20111260A1 (it) * 2011-07-06 2013-01-07 Carmelo Cutrupi Composizioni topiche per l'uso nella prevenzione e/o nel trattamento di dermatiti
US8343027B1 (en) 2012-01-30 2013-01-01 Ivivi Health Sciences, Llc Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant
CN105189451A (zh) * 2013-03-12 2015-12-23 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
EP3131628A4 (en) 2014-04-16 2017-11-22 Ivivi Health Sciences, LLC A two-part pulsed electromagnetic field applicator for application of therapeutic energy
CN105693817B (zh) * 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
WO2018089795A1 (en) 2016-11-10 2018-05-17 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT279052B (de) 1968-08-08 1970-02-25 Dragoco Gerberding Co Gmbh Lichtschutzmittel
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US3956361A (en) 1974-05-23 1976-05-11 Ciba-Geigy Corporation Hindered phenolic derivatives of norbornane thioalcohols
US4102995A (en) * 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
DE3025187A1 (de) * 1980-07-03 1982-02-11 Henkel KGaA, 4000 Düsseldorf Neue riechstoffe, deren herstellung sowie diese enthaltende riechstoffkompositionen
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
SE462139B (sv) * 1986-02-04 1990-05-14 Sven Moberg Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
DE3724691C2 (de) * 1987-07-25 1999-03-18 Konrad Minninger Pharmazeutisches Mittel zur lokalen Therapie von schuppenden Hautkrankheiten
US5352440A (en) * 1988-03-30 1994-10-04 Trustees Of Boston University Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof
US5700450A (en) * 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
DE3925634A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Stabilisatordispersionen
US5190978A (en) * 1989-09-29 1993-03-02 Dai-Ichi Kogyo Seiyaku Co. Ltd. Carcinostatic compositions and methods
JP3013540B2 (ja) 1990-09-18 2000-02-28 住友化学工業株式会社 害虫忌避剤
US5190798A (en) * 1992-01-09 1993-03-02 Gilbert Bloch Paper-plastic film, fiberglass-reinforced sealing tape
US5587402A (en) 1992-04-09 1996-12-24 Wisconsin Alumni Research Foundation Regression of mammalian leukemia cell tumors
US5414019A (en) 1992-04-09 1995-05-09 Wisconsin Alumni Research Foundation Regression of mammalian carcinomas
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
DE69331232T2 (de) * 1993-09-09 2002-07-25 E.I. Du Pont De Nemours And Co., Wilmington Wässrige Tintenzusammensetzung, die Mittel gegen das Einrollen von Papier enthält
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
US5626839A (en) * 1994-11-08 1997-05-06 Scales-Medeiros; Virginia Light responsive self-tanning products and methods for use
MX9800379A (es) * 1995-07-11 1998-03-31 Procter & Gamble Composiciones suavizadoras de telas, estables, dispersables en agua, concentradas.
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
ATE220318T1 (de) * 1996-02-21 2002-07-15 Stoa Sa Kosmetische, dermopharmazeutische oder tierärztliche zusammensetzungen zur antiseptischen behandlung von menschlicher oder tierischer haut
AU740783B2 (en) 1996-09-18 2001-11-15 Applied Genetics Incorporated Dermatics Pharmaceutical compositions and methods
WO1998055085A1 (en) * 1997-06-04 1998-12-10 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
CA2301016A1 (en) * 1997-08-21 1999-02-25 Johnson & Johnson Consumer Companies, Inc. Use of 17-.alpha.-estradiol for the treatment of aged or sundamaged ski n and/or skin atrophy

Also Published As

Publication number Publication date
AU4584297A (en) 1998-04-14
EP0957903B1 (en) 2005-08-10
US6294585B1 (en) 2001-09-25
ATE301459T1 (de) 2005-08-15
DE69733968T2 (de) 2006-06-01
US5990177A (en) 1999-11-23
EP0957903A1 (en) 1999-11-24
CA2266496A1 (en) 1998-03-26
DE69733968D1 (de) 2005-09-15
AU740783B2 (en) 2001-11-15
EP0957903A4 (en) 2002-10-09
ES2245465T3 (es) 2006-01-01
WO1998011882A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
DK0957903T3 (da) Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser
DE60144277D1 (de) Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
ATE50500T1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
ATE529109T1 (de) Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
ATE292121T1 (de) Chinazolinderivate
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
DK10389D0 (da) Fremgangsmaade til stimulering af haarvaekst
EP1043995A4 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED ARYL AND HETEROARYL HETEROCYCLIC UREAS
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE296309T1 (de) Wasserlösliche adenosin kinase inhibitoren
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
WO2005044179A8 (en) Formulations containing astragalus extracts and uses thereof
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
WO2002015870A3 (de) Substanzen zur induktion und intensivierung der bräuningsmechanismen der haut
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DK379886A (da) Praeparat og fremgangsmaade til behandling af svulster med udpg
NO20000007L (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å øke protein-kinase-B(PKB)- aktivitet
DK1137420T3 (da) Anvendelse af en kombination af et purin og en nitrogenmonooxiddonor til forebyggelse eller behandling af sexuel dysfunktion
ES8200886A1 (es) Procedimiento para la preparacion de derivados del amino-1 propanol-2
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor